


Alchemia gets new CEO

24 April 2013 | News | By BioSpectrum Bureau



Singapore: Brisbane drug discovery and development company Alchemia announces that Mr Charles Walker has been appointed to the position of Chief Executive Officer.

Mr Charles (Charlie) Walker BSC (Hons) Pharmacology, MBA has accepted the position effective immediately. Mr Walker, who has been Alchemia's Chief Financial Officer for the last two years, brings 20 years' international life science industry experience to the role.

ACL Chairman Dr Mel Bridges said: "The Board is delighted to have secured the services of a talented and experienced life sciences executive to lead the Company through what promises to be a critical development period. Charlie's financial, technical and operational background and proven leadership skills will support the delivery of key milestones, while maintaining a sharp focus on delivering shareholder value."

Mr Walker originally trained as a pharmacologist in the UK before embarking on a career in the pharmaceutical industry. He subsequently spent more than a decade in corporate finance advising international technology companies, executing more than 40 successful corporate transactions including IPOs, M&A agreements and fundraisings. He also co-founded a successful life sciences

investment banking firm in the UK which was sold to Nomura International plc in 2005 realising significant returns for investors.

Dr Bridges will resume his role as non executive chairman.

Mr Walker commented: "Alchemia is a fast growing, late stage drug development company with a bright, international future. The next 12 months will be transformative both in terms of clinical and corporate development and I am looking forward to building on the strong foundations already established, and continuing to work to unlock value for shareholders"